Sequella initiates dosing in Phase Ib tuberculosis trial - Pharmaceutical Business Review
Sequella initiates dosing in Phase Ib tuberculosis trial - Pharmaceutical Business Review - Sequella initiates dosing in Phase Ib tuberculosis trialPharmaceutical Business ReviewCarol Nacy, CEO of Sequella, said: "We are pleased to begin this Phase Ib safety trial and to continue the clinical development of SQ109, a potentially valuable new drug candidate for the treatment of both uncomplicated and drug resistant tuberculosis. ... [Google TB NEWS]
- Editor's blog
- Login or register to post comments


